| MAO | 1) MonoAmine Oxidase 2) Maximal Acid Output |
|---|---|
| MAOI | MonoAmine Oxidase Inhibitors |
| MA | malignant arrhythmia; management and administration; mandelic acid; masseter; Master of Arts; matern... |
| MAO | Master of the Art of Obstetrics; maximal acid output; monoamine oxidase |
| MAOA | monoamine oxidase A |
| MAO | Catechol-0-methyltransferase and monoamine oxidase |
|---|---|
| MAOI | Monoamine oxidase inhibitor |
| MAO | Monoamine Oxidase |
| MAO | Monoamine oxidase activity |
| MAO A | Monoamine oxidase type A |
| monoamine neurotransmitters | A group of naturally occurring amines derived by enzymatic decarboxylation of the natural amino acids. Many have powerful physiological effects (e.g., histamine, serotonin, epinephrine, tyramine). Those derived from aromatic amino acids, and also their synthetic analogs (e.g., amphetamine), are of use in pharmacology. (12 Dec 1998) |
|---|
| amino acid neurotransmitters | Amino acids released by neurons as intercellular messengers. Among the amino acid neurotransmitters are glutamate (glutamic acid) and gaba which are, respectively, the most common excitatory and inhibitory neurotransmitters in the central nervous system. (12 Dec 1998) |
|---|---|
| biogenic amine neurotransmitters | Biogenic amines released by neurons as intercellular messengers. The biogenic amines norepinephrine, dopamine, histamine, and serotonin are neurotransmitters in both the central and peripheral nervous systems. (12 Dec 1998) |
| monoamine | <biochemistry> A molecule containing one amine group. Synonym: monamine. (05 Mar 2000) |
| monoamine oxidase | <enzyme> Catalysing breakdown of several biogenic amines, such as serotonin, adrenaline, noradrenaline, dopamine. (18 Nov 1997) |
| monoamine oxidase inhibitor | <pharmacology> A drug that interferes with the action of monoamine oxidase, slowing the breakdown of certain neurotransmitters. Used in the treatment of depression. Monoamine oxidase inhibitors are a group of antidepressant drugs that prevent the activity of the enzyme monoamine oxidase in the central nervous system (brain) thus affecting mood. The use of these medications is often restricted due to their severe side effects and drug (and food) interactions. Examples include isocarboxazid, pargyline, selegiline, furazolidone and phenelzine. Acronym: MAOI (26 Mar 1998) |
| monoamine oxidase inhibitors | A chemically heterogeneous group of drugs that have in common the ability to block oxidative deamination of naturally occurring monoamines. Although mao inhibitors are probably as effective as tricyclic antidepressants in the treatment of major depression, the complex, sometimes severe, and often unpredictable interactions between mao inhibitors and many other drugs and food-derived amines make their medical use difficult and potentially hazardous. (12 Dec 1998) |
| neurotransmitters | Endogenous signaling molecules that alter the behaviour of neurons or effector cells. Neurotransmitter is used here in its most general sense, including not only messengers that act directly to regulate ion channels, but also those that act through second messenger systems, and those that act at a distance from their site of release. Included are neuromodulators, neuroregulators, neuromediators, and neurohumors, whether or not acting at synapses. (12 Dec 1998) |
| neurotransmitters and neurotransmitter agents | A collective grouping for neurotransmitters and substances that act on the neurotransmitter system. (12 Dec 1998) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|